CytomX Therapeutics, Inc. (CTMX) will report its next earnings on Aug 07 AMC. The company reported the earnings of $-0.64/Share in the last quarter where the estimated EPS by analysts was $-0.57/share. The difference between the expected and actual EPS was $-0.07/share, which represents an Earnings surprise of -12.3%.
Many analysts are providing their Estimated Earnings analysis for CytomX Therapeutics, Inc. and for the current quarter 10 analysts have projected that the stock could give an Average Earnings estimate of $-0.51/share. These analysts have also projected a Low Estimate of $-0.88/share and a High Estimate of $-0.26/share.
These analysts also forecasted Growth Estimates for the Current Quarter for CTMX to be 11.3%. They are projecting Next Quarter growth of 36.11%. For the next 5 years, CytomX Therapeutics, Inc. is expecting Growth of -27.48% per annum, whereas in the past 5 years the growth was 0.49% per annum.
Some buy side analysts are also providing their Analysis on CytomX Therapeutics, Inc., where 2 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)
When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for CytomX Therapeutics, Inc. might touch $30 high while the Average Price Target and Low price Target is $21 and $12 respectively.
CytomX Therapeutics, Inc. closed its last trading session at $8.86 with the gain of 8.01%. The Market Capitalization of the company stands at 438.59 Million. The Company has 52-week high of $22.50 and 52-week low of $8.07. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 6.02% where SMA50 and SMA200 are -6.28% and -21.65% respectively. The Company Touched its 52-Week High on 09/11/18 and 52-Week Low on 09/04/19.
The Relative Volume of the company is 0.94 and Average Volume (3 months) is 309.38 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.
The company shows its Return on Assets (ROA) value of -22.1%. The Return on Equity (ROE) value stands at -77.1%. While it’s Return on Investment (ROI) value is -70.4%.
While looking at the Stock’s Performance, CytomX Therapeutics, Inc. currently shows a Weekly Performance of 12.32%, where Monthly Performance is -5.71%, Quarterly performance is -4.2%, 6 Months performance is -7.98% and yearly performance percentage is -52.48%. Year to Date performance value (YTD perf) value is -36.62%. The Stock currently has a Weekly Volatility of 6.73% and Monthly Volatility of 5.88%.
Many analysts are providing their Estimated Earnings analysis for Nevada Gold & Casinos, Inc. and for the current quarter 0 analysts have projected that the stock could give an Average Earnings estimate of $0/share. These analysts have also projected a Low Estimate of $0/share and a High Estimate of $0/share.